05/2026. Cost-effectiveness of MV140
Published in the Canadian Urological Association Journal (CUAJ), this study demonstrates that the sublingual vaccine MV140 (INMUNOTEK) is a dominant alternative to prophylactic antibiotics for the prevention of recurrent urinary tract infections in adult women.
The results show that MV140 combines greater clinical benefit with a reduction in healthcare and societal costs associated with prolonged antibiotic treatment.
The study presents a pharmacoeconomic analysis comparing MV140 with conventional antibiotic prophylaxis in women with recurrent urinary tract infections. The model shows that MV140 reduces the number of infections, improves quality of life, and decreases the economic burden associated with antibiotic use and bacterial resistance. In addition, MV140 maintains a favorable cost-effectiveness profile across different clinical scenarios analyzed. These findings reinforce the value of non-antibiotic immunotherapeutic strategies in the management of recurrent urinary tract infections.
The study was conducted by R. Christopher Doiron and J. Curtis Nickel (Department of Urology, Queen’s University, Kingston, Ontario, Canada), together with Shivani Kamdar (PIVINA Consulting Inc., Mississauga, Ontario, Canada).










